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Introduction {#sec1}
============

Hematopoiesis is a tightly regulated process whereby all the blood cells arise from a pluripotent stem cell population. However, several mutations in hematopoietic stem cells have been identified that lead to deregulation of cellular differentiation and proliferation. In acute myeloid leukemia (AML), both chromosomal abnormalities and single gene mutations have been described to play a role in disease initiation, progression, and prognosis. Within the cytogenetically normal patients, mutations in genes that regulate DNA methylation including *IDH*, *DNMT3A* (20%--25%), and *TET2* (∼20%) have been thought to occur early on during leukemogenesis ([@bib1], [@bib3], [@bib26], [@bib14]). These loss-of-function mutations result in impaired differentiation and enhance the self-renewal of hematopoietic stem cells in mouse models can result in the development of chronic myelomonocytic leukemia (CMML)-like and myeloproliferative neoplasm (MPN)-like disease. Subsequent acquisition of additional mutations that provide proliferation and/or survival advantage to these preleukemic clones are required for their transformation to AML. One of the common mutation partners is Fms-like tyrosine kinase 3 (FLT3) with internal tandem duplication (ITD), leading to constitutive activation of this receptor tyrosine kinase. FLT3-ITD is present in ∼30% of AML patients and is considered an independent prognostic marker. AML patients with mutations in DNA-methylation regulators and FLT3-ITD constitute a poor prognosis group and often do not respond to conventional chemotherapy or kinase-targeted therapies ([@bib23]). Absence of relevant mouse models has hampered the progress in identifying the molecular approaches that will have better outcomes for these patients. To this end, we generated mice that co-express these mutations to find out whether they are sufficient for transformation from a CMML- and MPN-like disease to AML to obtain a better understanding of the earliest hematopoietic cells in the hierarchy to be affected.

TET methylcytosine dioxygenase *2* (*TET2*) plays an essential role in regulating the conversion of 5-methylcytosine to 5-hydroxymethylcytosine, which functions as an intermediate step for DNA demethylation. Loss of *Tet2* function is associated with increased promoter methylation and aberrant expansion of myeloid cells in different mouse models. The myeloid progenitor cells in *Tet2* mutant mice show impaired differentiation and demonstrate higher engraftment in transplant studies, indicating an increase in stem cell self-renewal abilities ([@bib28]). On the other hand, FLT3^*ITD*^ knockin mice show increased proliferation of hematopoietic stem cells, leading to increased numbers of myeloid cells ([@bib25]). In contrast to the *Tet2*^*−/−*^ mice, *Flt3*^*ITD/ITD*^ mice show defects in the competitive transplant setting, as stem cells derived from these mice are highly proliferative. Both of these mutations lead to expansion of the myeloid compartment, but the mice with single mutations do not develop AML. To mimic the co-occurrence and timing of expression of these two mutations in AML patients, we intercrossed these mice to bring the two mutations together and found that the double-mutant mice develop AML with complete penetrance and a short latency period. The transformation of CMML/MPN to AML occurred irrespective of the dosage of the two mutations.

While loss of *Tet2* and presence of *Flt3*^*ITD*^ in hematopoietic stem/progenitor cells (HSC/Ps) was capable of transforming hematopoietic stem cells in a cell-autonomous manner, we also found that the bone marrow (BM) niche plays an important role in regulating hematopoietic stem cell (HSC) behavior, which was significantly altered in the leukemic and preleukemic mice. Several recent studies ([@bib10], [@bib13], [@bib31]) have suggested that the BM microenvironment contributes to the clinical outcomes in MPN and AML patients by contributing to drug resistance. Alterations in the these BM niche cells results in changes in the milieu of soluble factors, and the newly acquired cellular composition can activate aberrant proliferation and migration of HSCs, leading to expansion of myeloid cells even in the absence of any mutations in HSCs ([@bib35]). Thus, the BM microenvironment not only protects leukemic cells from drugs but can also promote leukemogenesis in transplanted donor cells, accounting for disease relapse and donor-derived leukemia. Our mouse model shows that presence of germline mutations in *Tet2* and *FLT3*^*ITD*^ not only deregulates hematopoiesis at the earliest stem cell stage but also distorts the composition and soluble milieu of the BM niche to support the growth and survival of leukemic cells. Some of these changes in the BM niche become apparent in preleukemic mice that have loss of TET2 and are capable of promoting myeloid bias and expansion of even normal non-mutated hematopoietic cells. In summary, we describe physiologically relevant models of AML that are likely to have better predictive value for drug testing studies, and provide more information on essential features for transformation of CMML/MPN to AML.

Results {#sec2}
=======

Loss of Tet2 Followed by Expression of *Flt3*^*ITD/ITD*^ in BM Cells Leads to Development of Fatal AML {#sec2.1}
------------------------------------------------------------------------------------------------------

In humans, mutations in DNA-methylation regulator TET2 occur early on in preleukemic cells followed by acquisition of additional mutations, leading to the development of full-blown AML ([@bib33], [@bib39], [@bib40]). *FLT3*^*ITD/ITD*^ is one such common mutation that occurs subsequent to the acquisition of *TET2* mutations in humans ([@bib38], [@bib39]). However, it is unclear as to which cell-autonomous and non-autonomous changes take place when TET2 is lost early in development in H2SC/Ps prior to the acquisition of *FLT3*^*ITD/ITD*^. To study this, we intercrossed *Tet2*^*−/−*^ (global knockout of Tet2) mice with *Flt3*^*ITD/ITD*^-expressing mice (specifically expressed in hematopoietic cells) to generate *Tet2*^*−/−*^:*Flt3*^*ITD/ITD*^ compound mutant mice. *Tet2*^*−/−*^:*Flt3*^*ITD/ITD*^ mice showed significantly shorter survival compared with wild type (WT) or the single mutants of *Tet2*^*−/−*^ or *Flt3*^*ITD/ITD*^ ([Figure 1](#fig1){ref-type="fig"}A). Although the survival data for the single-mutant mice is consistent with the published literature demonstrating development of CMML-like disease with a median survival of over a year ([@bib28], [@bib25]), the median survival of *Tet2*^*−/−*^:*Flt3*^*ITD/ITD*^ mice was significantly reduced with all mice dead within 5 months post birth ([Figure 1](#fig1){ref-type="fig"}A). To further characterize *Tet2*^*−/−*^:*Flt3*^*ITD/ITD*^ mutant mice, we analyzed hematopoietic tissues of these mice at 4 months post birth, as the majority of these mice began to succumb around this time. White blood cell (WBC) counts and spleen size were significantly elevated in *Tet2*^*−/−*^:*Flt3*^*ITD/ITD*^ mutant mice compared with all the other groups, with neutrophils and monocytes being the major cell type responsible for elevated WBC counts ([Figures 1](#fig1){ref-type="fig"}B--1D). Importantly, only *Tet2*^*−/−*^:*Flt3*^*ITD/ITD*^ compound mutant mice showed a significant increase in KIT^+^CD11b^+^ myeloid blasts, suggesting that early loss of *Tet2* and acquisition of *Flt3*^*ITD/ITD*^ rapidly transforms preleukemic cells into AML ([Figures 1](#fig1){ref-type="fig"}E and 1F). Histopathological examination of BM, spleen, and liver further confirmed these observations as reflected by an increase in myeloid cell infiltration and loss of tissue architecture ([Figure S1](#mmc1){ref-type="supplementary-material"}). Neither *Tet2*^*−/−*^ nor *Flt3*^*ITD/ITD*^ mice by themselves led to such profound changes within this time span. Thus, early loss of Tet2 with subsequent acquisition of *Flt3*^*ITD/ITD*^ is capable of transforming preleukemic HSC/Ps into AML with a short latency period.Figure 1Loss of Tet2 with Concomitant Expression of *Flt3*^*ITD/ITD*^ in Mice Leads to Development of Fatal AML with a Short Latency Period(A) Kaplan-Meier survival curve for WT (n = 6), *Tet2*^−/−^ (n = 7), *Flt3*^*ITD/ITD*^ (n = 7), and *Tet2*^*−/−*^:*Flt3*^*ITD/ITD*^ (n = 10) mice.(B) Changes in peripheral blood counts of (i) WBCs, (ii) neutrophils, (iii) lymphocytes, (iv) monocytes, and (iv) RBCs (n = 6--7 mice per group).(C--F) (C) Spleen pictures and (D) Quantification of spleen weight (in grams) of 4-month-old WT, *Tet2*^*−/−*^, *Flt3*^*ITD/ITD*^, and *Tet2*^*−/−*^:*Flt3*^*ITD/ITD*^ mice (n = 6--7 mice per group). (E) Frequency of myeloid blasts in spleen (n = 3 mice per group). (F) Representative flow profiles of splenic myeloid blasts expressing C-KIT/CD11b.Data were collected from two independent experiments. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

*Tet2*^*−/−*^:*Flt3*^*ITD/ITD*^ Mice Show an Increase in BM Cellularity, Expansion of Myeloid Cell Compartment, and Defects in Maturation {#sec2.2}
-----------------------------------------------------------------------------------------------------------------------------------------

Since various peripheral hematopoietic compartments showed a significant expansion of myeloid cells in *Tet2*^*−/−*^:*Flt3*^*ITD/ITD*^ mice, we next examined whether this was observed in the BM as well. Consistent with the BM hypercellularity observed during the histopathological examination of *Tet2*^*−/−*^:*Flt3*^*ITD/ITD*^ mice, the total number of mononuclear cells were also significantly higher in *Flt3*^*ITD/ITD*^ and *Tet2*^*−/−*^:*Flt3*^*ITD/ITD*^ mice compared with WT mice, with *Tet2*^*−/−*^:*Flt3*^*ITD/ITD*^ mutant mice showing the greatest number of cells in the BM ([Figure 2](#fig2){ref-type="fig"}A). Increase in BM cellularity was accompanied with an increase in the frequency and absolute number of Gr-1 and CD11b single-positive myeloid cells ([Figures 2](#fig2){ref-type="fig"}B and 2C), with a concomitant reduction in B220/CD19 double-positive B cells ([Figures 2](#fig2){ref-type="fig"}D and 2E) in *Tet2*^*−/−*^:*Flt3*^*ITD/ITD*^ mice relative to other genotypes. While in WT the majority of BM myeloid cells were of a mature CD11b^+^GR1^+^ phenotype, in the *Flt3*^*ITD/ITD*^ and *Tet2*^*−/−*^:*Flt3*^*ITD/ITD*^ mice there was a significant increase in both the absolute number and frequency of cells that expressed only CD11b or GR1, and this phenotype was more pronounced in *Tet2*^*−/−*^:*Flt3*^*ITD/ITD*^ mice ([Figures 2](#fig2){ref-type="fig"}B, 2C, and 2G). Additionally, erythroid frequency of single-positive CD71 was found to be increased in *Flt3*^*ITD/ITD*^ and *Tet2*^*−/−*^:*Flt3*^*ITD/ITD*^ mice, with greater frequency in the *Tet2*^*−/−*^:*Flt3*^*ITD/ITD*^ mutant mice compared with *Flt3*^*ITD/ITD*^ mice ([Figures 2](#fig2){ref-type="fig"}F and 2G). While both of these groups showed a reduction in the development of mature Ter119^+^ erythroid cells ([Figures 2](#fig2){ref-type="fig"}G and 2F), accounting for the observed reduction in peripheral red blood cells (RBCs) ([Figure 1](#fig1){ref-type="fig"}), it was only in *Tet2*^*−/−*^:*Flt3*^*ITD/ITD*^ mice that a significantly decreased at pro-erythroblast (CD71^+^) stage was observed ([Figures 2](#fig2){ref-type="fig"}F and 2G). Similarly, development of B-lineage cells was severely affected by the presence of *Flt3*^*ITD/ITD*^ mutation, which is consistent with the published literature ([@bib25]). These results demonstrate that loss of *Tet2* followed by expression of *Flt3*^*ITD/ITD*^ in BM cells results in significant alterations in the maturation of multiple lineages including myeloid, erythroid, and lymphoid.Figure 2*Tet2*^*−/−*^:*Flt3*^*ITD/ITD*^ Mice Show Significant Increase in Bone Marrow Cellularity and Expansion of Myeloid Cell CompartmentBone marrow from 4-month-old WT, *Tet2*^*−/−*^, *Flt3*^*ITD/ITD*^, and *Tet2*^*−/−*^:*Flt3*^*ITD/ITD*^ mice were analyzed for committed mature cells by flow cytometry as described in [Experimental Procedures](#sec4){ref-type="sec"}.(A--C) (A) Bone marrow cellularity (n = 6--7 mice per group). (B) Frequency of (i) CD11b^+^, (ii) Gr1^+^/CD11b^+^, and (iii) Gr1^+^ myeloid cells in bone marrow (n = 4--6 mice per group). (C) Number of (i) CD11b^+^, (ii) Gr1^+^/CD11b^+^, and (iii) Gr1^+^ myeloid cells in bone marrow (n = 4--6 mice per group).(D--F) (D) (i) Frequency of B220^+^ and (ii) B220^+^/CD19^+^ lymphoid cells in bone marrow (n = 4--6 mice per group). (E) (i) Number of B220^+^ and (ii) B220^+^/CD19^+^ lymphoid cells in bone marrow (n = 4--6 mice per group). (F) (i) Frequency of CD71^+^, (ii) Ter119^+^/CD71^+^, and (iii) Ter119^+^ cells in bone marrow (n = 4--6 mice per group).(G) Representative flow profiles of erythroid, myeloid, and B cells in the bone marrow of indicated genotypes.

*Tet2*^*−/−*^:*Flt3*^*ITD/ITD*^ Mice Show Alterations in the Composition of Primitive Stem and Progenitor Cells in the BM {#sec2.3}
-------------------------------------------------------------------------------------------------------------------------

In an effort to assess how loss of *Tet2* followed by the expression of *Flt3*^*ITD/ITD*^ affects the composition of more primitive stem and progenitor cells in the BM, we analyzed the BM of *Tet2*^*−/−*^:*Flt3*^*ITD/ITD*^ mice. Both the absolute number and the frequency of Lin^−^Kit^+^sca1^−^ (LSK) fraction of the BM cells, which is enriched in hematopoietic stem cells, was significantly expanded in all three mutant mouse groups compared with WT controls. However, the magnitude of expansion of LSK cells was most dramatically altered in the BM and spleen of *Tet2*^*−/−*^: *Flt3*^*ITD/ITD*^ mice relative to other genotypes ([Figures 3](#fig3){ref-type="fig"}A--3D). The most profound changes were observed in *Tet2*^*−/−*^: *Flt3*^*ITD/ITD*^ mice. The BM of these mice showed an almost complete loss of long-term (LT)-HSCs (CD48^−^CD150^+^LSK) accompanied by an increase in short-term HSCs (CD48^+^CD150^−^LSK) ([Figures 3](#fig3){ref-type="fig"}E--3G). Thus, differentiation blockade caused by the combination of these mutations possibly exerts its effects at different stages of hematopoiesis.Figure 3Development of AML in *Tet2*^*−/−*^:*Flt3*^*ITD/ITD*^ Mice Is Due to Expansion of LSK CellsBone marrow and spleens were harvested from 4-month-old WT, *Tet2*^*−/−*^, *Flt3*^*ITD/ITD*^, and *Tet2*^*−/−*^:*Flt3*^*ITD/ITD*^ mice and analyzed for stem and progenitor cells by flow cytometry as described in [Experimental Procedures](#sec4){ref-type="sec"}.(A and B) (A) Frequency and (B) absolute number of Lin-Sca1^+^KIT^+^ (LSK) cells in the bone marrow (n = 4--6 mice per group).(C) Representative flow profiles of LSK cells in the bone marrow of indicated genotypes.(D) Frequency of LSK cells in the spleen of indicated genotypes (n = 3--5 mice per group).(E and F) (E) Frequency and (F) absolute number of CD48^−^CD150^+^LSK cells in the bone marrow of indicated genotypes (n = 3 mice per group).(G) Representative flow profiles of CD48^−^CD150^+^LSK cells in the bone marrow of indicated genotypes (n = 3 mice per group).

Heterozygous Loss of *Tet2* and Expression of Heterozygous *Flt3*^*ITD/*+^ or Homozygous *Flt3*^*ITD/ITD*^ in BM Stem and Progenitor Cells Results in the Development of AML but with Delayed Onset and Less Severity {#sec2.4}
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

In a subset of AML patients, often heterozygosity of *Tet2* along with heterozygous presence of *Flt3*^*ITD/*+^ is observed ([@bib37]). How *Tet2* heterozygosity as opposed to *Tet2* homozygosity cooperates with the expression of *Flt3*^*ITD/*+^ or *Flt3*^*ITD/ITD*^ in HSC/Ps was examined next. We generated mice of six different genotypes, namely WT, *Tet2*^+*/−*^, *Flt3*^*ITD/*+^, *Flt3*^*ITD/ITD*^, *Tet2*^+*/−*^:*Flt3*^*ITD/*+^, and *Tet2*^+*/−*^:*Flt3*^*ITD/ITD*^. At 4 months of age, we analyzed these mice for peripheral blood counts. As seen in [Figure S2](#mmc1){ref-type="supplementary-material"}A, no significant differences were observed in peripheral blood parameters between any of the four groups of mice involving *Tet2*^+*/−*^:*Flt3*^*ITD/*+^. In contrast, *Tet2*^+*/−*^:*Flt3*^*ITD/ITD*^ mice demonstrated a significant increase in both neutrophil and monocyte counts relative to rest of the genotypes in this group ([Figure S2](#mmc1){ref-type="supplementary-material"}B). Both *Flt3*^*ITD/ITD*^ and *Tet2*^+*/−*^:*Flt3*^*ITD/ITD*^ mice demonstrated a significant reduction in peripheral RBC counts relative to other genotypes ([Figure S2](#mmc1){ref-type="supplementary-material"}B). BM analysis revealed a significant increase in cellularity in *Tet2*^+*/−*^:*Flt3*^*ITD/*+^, *Flt3*^*ITD/ITD*^, and *Tet2*^+*/−*^:*Flt3*^*ITD/ITD*^ mice compared with WT or *Tet2*^+*/−*^ mice ([Figures S2](#mmc1){ref-type="supplementary-material"}C and S2D). A significant increase in spleen weight in both *Tet2*^+*/−*^:*Flt3*^*ITD/*+^ and *Tet2*^+*/−*^:*Flt3*^*ITD/ITD*^ mice was also observed relative to control mice ([Figures S2](#mmc1){ref-type="supplementary-material"}E and S2F). We next analyzed the frequency and absolute number of LSK cells in the BM of all six genotypes. As seen in [Figures S3](#mmc1){ref-type="supplementary-material"}A--S3D, the greatest increase in the absolute number of LSK cells was seen in *Tet2*^+*/−*^:*Flt3*^*ITD/*+^ and *Tet2*^+*/−*^:*Flt3*^*ITD/ITD*^ mice relative to other groups. We also examined erythroid and myeloid cells in the BM of six genotypes and observed the greatest increase in the frequency of CD71-positive erythroid cells in *Tet2*^+*/−*^:*Flt3*^*ITD/ITD*^ mice relative to other genotypes ([Figure S4](#mmc1){ref-type="supplementary-material"}). Similar observations were made in the myeloid and B cell compartment. However, in every case the changes in the size and distribution of various HSC/Ps and mature cells in the BM, spleen, or peripheral blood were dose dependent and most impressive in *Tet2*^*−/−*^:*Flt3*^*ITD/ITD*^, mice followed by *Tet2*^+*/−*^:*Flt3*^*ITD/ITD*^ mice and *Tet2*^+*/−*^:*Flt3*^*ITD/WT*^ mice.

At 8--10 weeks of age, 2 million BM cells from the six genotypes were injected into lethally irradiated recipients, and the mice were examined for survival. As seen in [Figure 4](#fig4){ref-type="fig"}A, starting on day 120 (4 months) post transplant, *Tet2*^+*/−*^:*Flt3*^*ITD/ITD*^ mice began to succumb to AML and all mice died by 210 days or 7 months post transplant. [Figure 4](#fig4){ref-type="fig"}B shows the spleens of WT, *Tet2*^*−/−*^, and *Tet2*^+*/−*^:*Flt3*^*ITD/ITD*^. We analyzed for non-hematopoietic components, as shown in [Figure 4](#fig4){ref-type="fig"}C, and observed: (1) heterozygous loss of *Tet2* along with co-occurrence of *Flt3*^*ITD/ITD*^ mutation, showing greater expansion of mesenchymal stem cells (MSCs); and (2) significant expansion of endothelial cells (ECs) in *Tet2*^+*/−*^ and a trend toward additive on co-occurrence with *Flt3*^*ITD/ITD*^ mutation. To evaluate the functional impact of *Tet2* loss alone or in combination with *Flt3*^*ITD*^ (*Tet2*^−/−^:*Flt3*^*ITD/*+^) on osteoclasts, we performed tartrate-resistant acid phosphatase (TRAP) staining on femurs from WT, *Tet2*^−/−^, and *Tet2*^*−/−*^:*Flt3*^*ITD/*+^ primary mice. As shown in [Figure 4](#fig4){ref-type="fig"}D, presence of increased TRAP staining was observed in *Tet2*^*−/−*^ and *Tet2*^−/−^:*Flt3*^*ITD/*+^ femurs compared with WT, which also supports the *in vitro* TRAP data ([Figure 4](#fig4){ref-type="fig"}F, upper panel) and suggests that osteoclasts potentially contribute to the leukemic phenotype. Next, we assessed the impact of *Tet2*^*−/−*^ and *Tet2*^−/−^:*Flt3*^*ITD/*+^ mutations on the development of osteoblast cells (OBCs) by alkaline phosphatase assay on cultured cells derived from WT, *Tet2*^−/−^, and *Tet2*^*−/−*^:*Flt3*^*ITD/*+^ primary mice. Greater proliferating OB activity was found in *Tet2*^*−/−*^ and *Tet2*^−/−^:*Flt3*^*ITD/*+^ cultures compared with WT controls, as shown in the lower panels of [Figure 4](#fig4){ref-type="fig"}F. A greater number of monocyte/macrophage precursors from *Tet2*^*−/−*^ and *Tet2*^−/−^:*Flt3*^*ITD/*+^ mice might possibly be contributing to differentiation of cells into osteoclast bone-resorbing cells and greater bone nodule formation, as shown by Vonkossa staining on femurs, thereby inducing greater bone remodeling ([Figure 4](#fig4){ref-type="fig"}E).Figure 4Heterozygosity or Homozygosity of *Flt3*^*ITD*^ along with Concomitant Heterozygosity of *Tet2* Results in AML Development with Similar Latency(A) Primary bone marrow transplantation. Two million bone marrow mononuclear cells isolated from WT, *Tet2*^+*/−*^, *Flt3*^*ITD/ITD*^, and *Tet2*^+*/−*^:*Flt3*^*ITD/ITD*^ mice were transplanted into lethally irradiated C57BL/6 mice through tail vein injection and monitored for disease progression, and Kaplan-Meier survival was established (n = 5 mice per group). See also [Figure S3](#mmc1){ref-type="supplementary-material"}.(B) Pictures of spleens from indicated genotypes. See also [Figures S2](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}.(C) Mesenchymal stem cells and endothelial cells were analyzed in primary mice by flow cytometry (n = 3 mice). In brief, bones from WT, *Tet2*^+*/−*^, and *Tet2*^+*/−*^:*Flt3*^*ITD/ITD*^ mice were subjected to collagenase digestion followed by staining for mesenchymal stem cells (CD45^*Neg*^, Lin^*Neg*^, CD31^*Neg*^, Sca1^*Pos*^, CD51^*Pos*^), endothelial cells (CD45^*Neg*^, Lin^*Neg*^, CD31^*Pos*^), and osteoblastic lineage cells (CD45^*Neg*^, Lin^*Neg*^, CD31^*Neg*^, Sca1^*Neg*^, CD51^*Pos*^). See also [Figure S5](#mmc1){ref-type="supplementary-material"}.(D) Images of tartrate-resistant acid phosphatase (TRAP) staining on femurs from the primary mice of the indicated genotypes (n = 3 biological replicates).(E) Images of Vonkossa staining on femurs from the primary mice of the indicated genotypes (n = 3 biological replicates).(F) Representative images of TRAP staining (upper panels) and nitroblue tetrazolium/5-bromo-4-chloro-3-indolyl-phosphate (NBT/BCIP) staining (lower panels) from *in vitro* cultures of indicated genotypes (n = 3 independent experiments).

Interestingly, mice transplanted with BM cells derived from *Tet2*^+*/−*^:*Flt3*^*ITD/*+^ mice also began to succumb around the same time as *Tet2*^+*/−*^:*Flt3*^*ITD/ITD*^ mice, and all were dead by 7 months ([Figure S3](#mmc1){ref-type="supplementary-material"}E). At 4 months post primary transplant, BM cells derived from the primary transplanted recipients were transplanted into lethally irradiated secondary hosts. As seen in [Figures S3](#mmc1){ref-type="supplementary-material"}F and S3G, these recipients began to succumb around day 90 (3 months), and all mice were dead by 160 days (5 months). These results illustrate that haploinsufficiency or homozygosity of *Flt3*^*ITD*^ cooperates equally well with Tet2 heterozygosity in the development of AML and overall survival.

Loss of *Tet2* Alters the BM Microenvironment and Produces More Pro-inflammatory Cytokines {#sec2.5}
------------------------------------------------------------------------------------------

There is increasing evidence ([@bib17], [@bib35]) of crosstalk between leukemic cells and their microenvironment whereby both can modulate each other to support the survival of leukemic cells and disease development. We next assessed the BM composition of *Tet2*^*−/−*^ mice by examining the frequency of MSCs, ECs, and OBCs, three cell types that can influence the growth and survival of both normal and leukemic cells. As seen in [Figures 5](#fig5){ref-type="fig"}A--5C, a significant increase in the frequency of all three cell types was observed in *Tet2*^*−/−*^ mice. Furthermore, loss of TET2 also resulted in significant alteration in the expression levels of various pro-inflammatory cytokines that have been implicated in regulating HSC/P functions including interleukin-5 (IL-5), IL-6 and CXCL5, which were all elevated in the absence of *Tet2*, and macrophage inflammatory protein 1A (MIP-1A), MIP-1B, MIP-2, tumor necrosis factor α (TNFα), IL-13, and IL-15, which were all downregulated in these mice compared with controls ([Figures 5](#fig5){ref-type="fig"}D--5I). High levels of TNFα are detrimental to the propagation of stem cells. A recent study in *Flt3*^*ITD*^ mice ([@bib29]) showed increased levels of TNFα and its association with stem cell exhaustion. Thus, less TNFα, as seen in our model, may contribute to better propagation and maintenance of overall hematopoiesis. IL-13 plays a critical role in B cell maturation and differentiation. IL-15 is a known mitogen and survival factor for T cells. In the absence or inhibition of IL-15, T cell immunity is likely to be affected. Studies ([@bib8], [@bib42], [@bib18], [@bib19]) demonstrate that TET2-mediated demethylation controls cytokine expression in T helper cells. Consistent with this notion, our AML mice are likely to have poor anti-tumor immunity due to the presence of possibly increased numbers of T suppressor cells.Figure 5Loss of Tet2 Alters the Composition of the Bone Marrow Microenvironment and Cytokine Production(A--C) Bones were harvested from 3-month-old WT and *Tet2*^*−/−*^ mice (n = 4--5) and subjected to collagenase digestion followed by staining for (A) mesenchymal stem cells, (B) endothelial cells, and (C) osteoblastic lineage cells, and analyzed by flow cytometry. Cytokines and chemokines from serum of 3-month-old WT and *Tet2*^*−/−*^ mice were assayed using mouse 32-plex cytokine/chemokine array.(D--I) (D) Cxcl5, (E) IL-1α, and (F) IL-5 and IL-6 were increased and (G) IL-13 and IL-15, (H) TNFα, and (I) MIP1α, MIP1β, and MIP2 were decreased. Concentrations are presented in pg/mL (n = 3--5 mice per genotype).Student's unpaired t test was performed for statistical significance (^∗^p \< 0.05, ^∗∗^p \< 0.001).

Altered BM Microenvironment in *Tet2*^*−/−*^ Mutant Mice Supports the Expansion of Leukemic Cells {#sec2.6}
-------------------------------------------------------------------------------------------------

Given the nature of changes in the composition of BM microenvironment in mice bearing loss of TET2, including enhanced frequency of MSCs, ECs, and OBCs in addition to cytokines, we asked whether transplanting normal BM cells or BM cells derived from mice bearing a key mutation associated with AML, such as *Flt3*^*ITD/ITD*^ into *Tet2*-deficient mice, would support the growth of these cells or not. We took 2 million BM cells from WT or *Flt3*^*ITD/ITD*^ mice and transplanted them into lethally irradiated WT or *Tet2*^*−/−*^ mice, and monitored the engraftment ([Figure 6](#fig6){ref-type="fig"}A). At 5 months post transplant, mice were sacrificed and analyzed. As seen in [Figures 6](#fig6){ref-type="fig"}B and 6C, BM derived from *Flt3*^*ITD/ITD*^ mice, when transplanted into *Tet2*^*−/−*^ recipients, resulted in the development of largest spleen size and weight relative to all other experimental groups. In the BM, a profound increase in the frequency as well as in the absolute number of LSK cells was noted when *Flt3*^*ITD/ITD*^ cells were transplanted into *Tet2*-deficient recipients ([Figure 6](#fig6){ref-type="fig"}D).Figure 6Altered Bone Marrow Microenvironment in Preleukemic *Tet2*^*−/−*^ Mice Supports the Expansion of Myeloid Malignant *Flt3*^*ITD/ITD*^-Bearing Cells(A) Schematic showing transplantation of normal WT or *Flt3*^*ITD/ITD*^-bearing cells to normal WT or preleukemic Tet*2*^*−/−*^ mice. Bone marrow cells (2 × 10^6^) isolated from WT or *Flt3*^*ITD/ITD*^ mice were transplanted into lethally irradiated WT or *Tet2*^*−/−*^ mice through tail vein and monitored for disease progression. Reconstitution of hematopoietic stem and progenitor cells was analyzed 5 months after transplantation.(B) Photos of representative spleens from transplanted mice.(C) Spleen weights (6--11 mice in each group).(D) (i) Representative flow profile of LSK cells in the bone marrow of indicated transplanted mice, (ii) Frequency and (iii) number of LSK cells in the bone marrow.(E) Bone marrow frequency of indicated genotypes of (i) Gr1^+^/CD11b^+^, (ii) Gr1^+^, and (iii) CD11b^+^ myeloid cells.(F) Frequency of (i) B220^+^/CD19^+^ and (ii) B220^+^ in bone marrow of indicated mice.(G) Spleen frequency of indicated genotypes of (i) Gr1^+^/CD11b^+^, (ii) Gr1^+^, and (iii) CD11b^+^ myeloid cells.(H) Frequency of (i) B220^+^/CD19^+^ and (ii) B220^+^ in spleen of indicated mice.Data were collected from two independent experiments. See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

We next examined the impact of *Tet2*-deficient recipients transplanted with WT or *Flt3*^*ITD/ITD*^ BM cells to give rise to more mature myeloid and lymphoid cells. In the BM, we found a significant increase in the presence of Gr-1/CD11b double-positive cells when *Flt3*^*ITD/ITD*^ cells were transplanted into *Tet2*-deficient recipients relative to all other groups ([Figure 6](#fig6){ref-type="fig"}E). Consistent with our findings in the marrow, a much more pronounced expansion of Gr-1/CD11b double-positive as well as CD11b single-positive cells was noted in *Tet2*^*−/−*^ mice transplanted with *Flt3*^*ITD/ITD*^ BM cells in the spleen ([Figure 6](#fig6){ref-type="fig"}G). Representative flow profiles in the BM and spleen of transplanted mice in the four experimental groups are shown in [Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B. We also examined the contribution of B cells in the four transplanted groups. As seen in [Figures 6](#fig6){ref-type="fig"}F and 6H, a significant decrease in the production of B cells was noted in both the BM and the spleen of *Tet2*^*−/−*^ recipient mice transplanted with *Flt3*^*ITD/ITD*^ BM cells, as assessed by the decrease in frequency of B220/CD19 double-positive cells. A similar finding was observed when *Flt3*^*ITD/ITD*^ BM cells were transplanted into WT recipients. These results suggest that the defects observed in B cell development and maturation associated with *Flt3*^*ITD/ITD*^-bearing HSC/Ps are mainly cell intrinsic and not dependent on the microenvironment, although a modest but significant further reduction in the B220/CD19 double-positive cells was noted in *Tet2*^*−/−*^ recipients transplanted with *Flt3*^*ITD/ITD*^ cells ([Figure 6](#fig6){ref-type="fig"}H).

Tet2-Deficient Myeloid Progenitors Expand in Recipient Mice Lacking a Combination of Tet2 and Expressing *Flt3*^*ITD/*+^ {#sec2.7}
------------------------------------------------------------------------------------------------------------------------

To assess how *Tet2*^*−/−*^ preleukemic BM cells grow in a microenvironment with AML driven by a combination of *Tet2*^*−/−*^:*Flt3*^*ITD/*+^ mutations, we transplanted 2 million BM cells from 7 to 8 month-old *Tet2*^*−/−*^ mice into lethally irradiated age-matched WT or *Tet2*^*−/−*^:*Flt3*^*ITD/*+^ mice and monitored the engraftment of donor cells. Six weeks after transplantation, mice were sacrificed on account of moribund features. As shown in [Figure 7](#fig7){ref-type="fig"}B, phenotypic analysis of BM cells derived from *Tet2*^*−/−*^:*Flt3*^*ITD/*+^ recipients showed an elevated number of myeloid progenitor (GMP) cells relative to controls. The frequency of mature myeloid Gr1/CD11b was also increased in the BM ([Figure 7](#fig7){ref-type="fig"}C) and spleen ([Figure 7](#fig7){ref-type="fig"}F) of *Tet2*^*−/−*^:*Flt3*^*ITD/*+^ recipients compared with controls; whereas the frequency of lymphoid cells (B220) was reduced ([Figures 7](#fig7){ref-type="fig"}D and 7G). [Figures 7](#fig7){ref-type="fig"}E and 7H show representative flow profiles of myeloid and lymphoid cells in *Tet2*^*−/−*^:*Flt3*^*ITD/*+^-recipient mice transplanted with *Tet2*^*−/−*^ cells. Next, we performed coculture assay to assess the relative contribution of OBCs in supporting the growth of *Tet2*^−/−^:*Flt3*^*ITD/*+^ cells. As shown in [Figure 7](#fig7){ref-type="fig"}I, an increase in colony-forming units (CFU) was observed when purified lineage-negative *Tet2*^−/−^:*Flt3*^*ITD/*+^ cells were cocultured with OBCs derived from *Tet2*^−/−^:*Flt3*^*ITD/*+^ mice compared with OBCs derived from *Tet2*^−/−^ and/or WT OBCs. Furthermore, to test whether *Tet2*^−/−^:*Flt3*^*ITD/ITD*^ BM supports the survival of WT cells better than preleukemic *Tet2*^*−/−*^ cells, we transplanted *Tet2*^*−/−*^:*Flt3*^*ITD/ITD*^ cells into WT and *Tet2*^*−/−*^ recipients and followed their survival. Four *Tet2*^*−/−*^ recipients out of five that were transplanted with *Tet2*^*−/−*^:*Flt3*^*ITD/ITD*^ cells died 15 days post transplantation and one was moribund after 93 days. None of the WT recipients transplanted with *Tet2*^*−/−*^:*Flt3*^*ITD/ITD*^ cells were found dead ([Figure 7](#fig7){ref-type="fig"}J), suggesting that *Tet2*^*−/−*^:*Flt3*^*ITD/ITD*^ leukemic cells survive better in the normal WT microenvironment but die when exposed to the preleukemic *Tet2*^*−/−*^ microenvironment. Significantly elevated peripheral WBCs, neutrophils, lymphocytes, and monocyte counts and percentages were found in one of the surviving *Tet2*^*−/−*^ recipients compared with four of the WT recipients, as presented in [Figure S7](#mmc1){ref-type="supplementary-material"}E (table). To rule out the possibility of age-associated leukemic transformation contributing to pro-leukemogenic phenotype, we transplanted 2 million BM cells from 2- to 3-month-old *Tet2*^*−/−*^ mice to lethally irradiated age-matched WT and *Tet2*^*−/−*^:*Flt3*^*ITD/*+^ recipients and analyzed them for hematopoietic and non-hematopoietic stromal components at 36 weeks after transplantation. As shown in [Figures S7](#mmc1){ref-type="supplementary-material"}A--S7D, peripheral blood platelet counts are decreased with significantly increased frequency of CD11b BM cells, ECs, and OBCs cells in the *Tet2*^*−/−*^:*Flt3*^*ITD/*+^ recipients relative to WT controls, suggesting that CD11b, ECs, and OBCs may all contribute to the malignant phenotype. Taken together, these data show that when preleukemic *Tet2*-deficient BM cells are exposed to leukemic microenvironment driven by *Tet2*^*−/−*^:*Flt3*^*ITD/*+^ mutations, MPN-like features are manifested.Figure 7Expansion of *Tet2*^*−/−*^ Myeloid Cells but Not B Cells in the Bone Marrow of *Tet2*^*−/−*^:*Flt3*^*ITD/*+^ Mice(A) Schematic showing preleukemic Tet2 cells exposed to normal WT or leukemic *Tet2*^*−/−*^:*Flt3*^*ITD/*+^ microenvironment. Two million bone marrow cells isolated from *Tet2*^*−/−*^ mice were transplanted into lethally irradiated WT or *Tet2*^*−/−*^:*Flt3*^*ITD/*+^ mice through tail vein and monitored for disease progression. Mice were analyzed 6 weeks after transplantation.(B) (i) Absolute number of granulocyte/macrophage progenitor cells (GMP) in the bone marrow of indicated recipients. (ii) Representative flow profile of various bone marrow progenitors in the indicated recipients. CMP, common myeloid progenitor cells. MEP, megakaryocyte erythroid progenitor cells.(C--E) (C) Frequency of Gr1^+^/CD11b^+^ myeloid cells in the bone marrow of indicated recipients and (D) frequency of B220^+^ lymphoid cells in bone marrow of indicated recipients. (E) Representative flow profile of myeloid and lymphoid cells in the bone marrow of recipient mice.(F and G) (F) Frequency of Gr1^+^/CD11b^+^ myeloid cells in the spleen of indicated recipients and (G) frequency of B220^+^ lymphoid cells in spleen of indicated recipients.(H) Representative flow profile of myeloid and lymphoid cells in the spleen of recipient mice. Student's t test was performed for statistical significance (^∗^p \< 0.05, n = 3--4 mice in each group).(I and J) (I) Coculture assay. In brief, bones from WT and *Tet2*^*−/−*^:*Flt3*^*ITD/*+^ after flushing marrow were subjected to collagenase digestion. Lineage-negative, CD45-negative stromal cells were sorted (4,000 cells/well) directly into 12-well plates containing DMEM, 15% FBS, 100 U penicillin/100 μg streptomycin, and 50 mM 2-mercaptoethanol. OBCs were induced by adding 3 mM β-glycerophosphate and 10mg/mL L-ascorbic acid phosphate. After 24 h, lineage-negative bone marrow cells from WT and *Tet2*^−/−^:*Flt3*^*ITD/*+^ mice were added to the pre-established OBCs and cocultured for another 4 days in the presence of SCF (25 mg/mL), Flt3 ligand (25 mg/mL), and IL-11 (25 mg/mL). After 4 days, CFU activity in methylcellulose was assessed from all the cells including adherent OBCs, and colonies were counted after 7 days. Statistical analysis was performed by one-way ANOVA with uncorrected Fisher\'s test. ^∗∗^p \< 0.001, ^∗∗∗^p \< 0.0001. (J) Two million bone marrow mononuclear cells from *Tet2*^*−/−*^: *Flt3*^*ITD/ITD*^ mice was transplanted to lethally irradiated 5-month-old WT (n = 4) and *Tet2*^*−/−*^ (n = 5) mice, and their survival was monitored. Peripheral blood counts from the surviving WT recipients and moribund *Tet2*^*−/−*^ recipients are presented in [Figure S7](#mmc1){ref-type="supplementary-material"}E.

Discussion {#sec3}
==========

In addition to genetic and epigenetic changes in BM progenitors, accumulating evidence suggests a role for the BM microenvironment in the development of MPN and AML ([@bib24]). Using a transgenic BCR/ABL mouse model of chronic myeloid leukemia (CML), [@bib35] investigated the role of MPN in the regulation of the endosteal BM niche and found that leukemic myeloid cells induce the expansion of OBCs from MSCs and contribute to BM fibrosis. These studies suggest a contribution of the BM microenvironment to MPN development, and therapeutic intervention of both leukemic cells and the BM microenvironment may be necessary for the complete elimination of leukemia-initiating cells. Thus, understanding the role of BM microenvironment cells in the development of MPN and AML is necessary for developing better therapies to treat these diseases. Although genetic and *in vivo* studies on the role of *Tet2* loss in cooperation with *Flt3*^*ITD/ITD*^ and in inducing AML have been conducted ([@bib36]), the *in vivo* effects of early and ubiquitous loss of *Tet2* followed by expression of *Flt3*^*ITD/ITD*^ in these same cells and their impact on the function of the BM microenvironment has not previously been described. First, we found that loss of *Tet2* and constituent activation of *Flt3*^*ITD/ITD*^ in BM cells causes a lethal AML phenotype with a latency of less than 200 days. Utilizing a VavCre Tet2^−/−^/Flt3^*ITD*^, [@bib36] reported a long survival of 600 days. Second, we observed altered BM microenvironment cell composition including in the ECs and MSCs in *Tet2*^+*/−*^:*Flt3*^*ITD/ITD*^ mice. Third, we observed expansion of pro-inflammatory cytokines and hyperproliferation of *Flt3*^*ITD/ITD*^ donor cells in the preleukemic microenvironment.

In VavCre-driven *Tet2*^*−/−*^:*Flt3*^*ITD/ITD*^ mice, TET2 is deleted in HSCs specifically and partly on ECs whereas in our model system, TET2 is deleted globally including MSCs and OBCs, which play a critical role in the expansion of leukemic cells and disease progression, thus contributing to a shorter latency. Our results in regard to the composition of microenvironment cell composition shows an increase in the frequency of endothelial, mesenchymal, and osteoblastic lineage cells in preleukemic *Tet2*^*−/−*^ mice compared with WT mice, suggesting that the loss of TET2 in these cell types is a prerequisite for an aggressive lethal AML phenotype. Our data are consistent with those of [@bib36] with respect to cell-autonomous features including increase in WBCs, neutrophils, and monocytes, and a reduction in RBCs. Increase in BM cellularity, expansion of LSK cells in the BM and spleen, reduction in LT-HSCs, increase in c-kit/CD11b double-positive myeloid blasts, and accumulation of CD71, Gr1, and CD11b single-positive cells in the BM are all features consistent with those observed by [@bib36] utilizing a different model of *Tet2*^*−/−*^:*Flt3*^*ITD/ITD*^. While loss of *Tet2* and expression of *Flt3*^*ITD*^ in BM stem/progenitor cells might be required for disease initiation in a cell-autonomous manner; AML blasts might occupy and alter the BM niche composition leading to secretion of several pro-inflammatory cytokines, which are likely to function as growth-promoting factors for the growth of leukemic cells while repressing normal hematopoiesis. [@bib27] showed that conditional deletion of *Tet2* in mesenchymal cells results in accelerated malignant progression and shortened survival. Other studies ([@bib9], [@bib35]) in CML and MPN model systems have shown that leukemic myeloid cells induce the expansion of OBCs from MSCs and secretion of several pro-inflammatory factors.

While screening AML patients\' plasma [@bib31] observed higher levels of IL-5, IL-6, and IL-10, including an inverse correlation between survival and plasma levels of IL-6 and IL-10. Several additional studies have shown that pro-inflammatory cytokines and growth factors play a crucial role in myeloid malignances by supporting the growth and survival of leukemic cells ([@bib30], [@bib43]). In our studies, loss of *Tet2* resulted in significant increase in the expression of IL-5 and IL-6 and a reduction in IL-10 levels, implicating a role for these cytokines in the pathogenesis of AML driven by loss of *Tet2* and expression of *Flt3*^*ITD*^. IL-5 produced by mast cells, T cells, and eosinophils and has been shown to play an important role in eosinophilia ([@bib4], [@bib32]). Our peripheral blood counts in *Tet2*^*−/−*^:*Flt3*^*ITD/ITD*^ mice also showed increased levels of eosinophils, correlating with an increase in IL-5 levels, which could be a consequence of cell-mediated immunity against progression of lethal AML. Furthermore, elevated frequency of microenvironmental cells observed in *Tet2*^*−/−*^ might also contribute to more cytokine production, thereby contributing to the aggressive AML phenotype seen in the current study. Several studies ([@bib2], [@bib6]) have shown that MSCs inhibit B cell proliferation, differentiation, and immunoglobulin production. Our data on phenotypic analysis of *Tet2*^*−/−*^:*Flt3*^*ITD/ITD*^ show reduced frequency of B220/CD19 double-positive cells but not single B220-positive cells in the BM, suggesting that the elevated numbers of MSCs/OBCs in the stroma of these animals might be critical for the maturation of B cells.

Tet2 mutations are shown to be present in both hematopoietic and non-hematopoietic malignancies. It is not clear whether the coexistence of hematopoietic and non-hematopoietic cancers occurs in the same individual because of *Tet2* mutations. Given that cellular alterations are interrelated and occur simultaneously, the extent to which monocytes, ECs, or OBCs play an important role over another is not clear. [@bib15], and [@bib20] showed that loss of *Tet2* results in enhanced recruitment of monocytes, which has been linked to accelerated atherosclerosis through increased production of cytokines and chemokines. [@bib7] showed that TET2 restrains inflammatory gene expression in macrophages; suggesting the possibility of altered microenvironment. ECs play a critical role in HSC maintenance. [@bib11] have shown an increased number of ECs in AML spleens and that AML progression leads to differential remodeling of vasculature by producing pro-inflammatory and anti-angiogenic cytokines. [@bib5] showed that functional integration of AML cells can either differentiate into endothelial-like cells or fuse with established endothelium. Osteoblasts play a critical role in the maintenance and expansion of HSC/Ps as well as oncogenic transformation ([@bib9], [@bib21], [@bib22]).

In summary, our mouse genetics studies show that loss of function of *Tet2* in cooperation with *Flt3*^*ITD/ITD*^ expression have pathogenic effects on the BM microenvironment and on resident HSCs in promoting leukemogenesis. Our coculture data and transplantation data correlate with enhanced CD11b, EC, and OBC activity and/or numbers in *Tet2*^*−/−*^:*Flt3*^*ITD/*+^ mice ([Figures 7](#fig7){ref-type="fig"}I and [S7](#mmc1){ref-type="supplementary-material"}B--S7D) suggesting that CD11b, ECs, and OBCs also contribute to the malignant phenotype.

Overall, our data support the notion that leukemic cells alter the BM niche by altering the microenvironmental cell composition and secretion of pro-inflammatory cytokines, which can promote the growth and survival of leukemic cells. Therapeutic strategies including reversing the damage caused to the niche by leukemia cells should be considered as part of the treatment process, while considering elimination of fertile ground for disease recurrence may be equally essential.

Experimental Procedures {#sec4}
=======================

Mice {#sec4.1}
----

All animal procedures were conducted in accordance with the Guidelines for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee at Indiana University School of Medicine. The mice were housed in pathogen-free conditions at the Indiana University Laboratory Animal Research Center (Indianapolis, IN, USA). *Flt3*^*ITD/ITD*^ mice ([@bib25]) were crossed with *Tet2*^*−/−*^ mice([@bib28]) to generate the double-mutant mice. WT (C57BL/6) mice were procured from the In Vivo Core facility at Indiana University.

Flow-Cytometry Analysis {#sec4.2}
-----------------------

Immunophenotyping was performed as described previously ([@bib16]). Preparation of single-cell suspension and staining is described in [Supplemental Information](#app1){ref-type="fn"}.

Preparation of Stroma and Microenvironmental Cell Staining {#sec4.3}
----------------------------------------------------------

Mesenchymal cells, ECs, and osteoblastic lineage cells from stroma were stained for flow cytometry following collagenase digestion of bone fragments as described earlier ([@bib41], [@bib35]).

Acid and Alkaline Phosphatase Assay {#sec4.4}
-----------------------------------

TRAP and Vonkossa staining were done on femurs from 22-week-old from WT, *Tet2*^*−/−*^, and *Tet2*^*−/−*^:*Flt3*^*ITD/*+^ mice following the methods of [@bib12] and [@bib34] at Indiana University School of Medicine Histology Core Facility. For *in vitro* experiments CD45-negative, lineage-negative stromal cells from collagenase digested bone cells were sorted directly into 12-well plates containing DMEM, 15% fetal bovine serum (FBS), 100 U penicillin/100 μg streptomycin, and 50 mM β-mercaptoethanol. Osteoblasts were induced by addition of 3 mM β-glycerophosphate and 10 mg/mL L-ascorbic acid-2-phosphate, and cultured for 2 weeks before TRAP staining was performed as per manufacturer\'s instructions (Sigma-Aldrich Kit, cat. \#387A). Osteoclasts were cultured for 3 weeks and BCIP/NBT (5-bromo-4-chloro-3-indolyl-phosphate/nitroblue tetrazolium) staining was performed for alkaline phosphatase activity following manufacturer's instructions (Thermo Scientific, cat. \#34042).

BM Transplantation {#sec4.5}
------------------

Two million whole BM mononuclear cells isolated from WT, *Tet2*^+*/−*^, *Flt3*^*ITD/WT*^, *Flt3*^*ITD/ITD*^, *Tet2*^+*/−*^:*Flt3*^*ITD/WT*^, and *Tet2*^+*/−*^:*Flt3*^*ITD/ITD*^ were transplanted into lethally irradiated C57BL/6 mice through the tail vein and monitored for disease progression.

Serum Cytokine Profiling {#sec4.6}
------------------------

Serum was separated from peripheral blood and subjected to serum cytokine bioplex analysis through Eve Technologies (Canada). Results are expressed as pg/mL of serum.

Statistical Analysis {#sec4.7}
--------------------

Median values of each group are shown with interquartile range. Each data point represents the value from individual mice in their respective groups in [Figures 1](#fig1){ref-type="fig"}, [2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"}, [4](#fig4){ref-type="fig"}, and [6](#fig6){ref-type="fig"}. Error bars indicate the standard error of the mean in [Figures 5](#fig5){ref-type="fig"} and [7](#fig7){ref-type="fig"}. Statistical analysis was performed using GraphPad version 7 by one-way ANOVA with uncorrected Fisher\'s test for multiple groups and Student\'s t test between two groups. p values in figures are denoted by ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, and ^∗∗∗∗^p \< 0.0001.
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